Palivizumab shows promise for preventing repeated wheezing in preemies

10/14/2013 | DailyRx.com

Babies born between 33 weeks and 35 weeks of gestation who were given palivizumab within their first six months of life were less likely to develop recurrent wheezing during their first three years than those who did not get the medication, a Japanese study in the journal Pediatrics showed. Of the 349 babies in the palivizumab group, 6.4% had repeated wheezing compared to nearly 19% in the control group.

View Full Article in:

DailyRx.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ